Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical’s subsidiary has initiated a Phase III clinical trial for Luvometinib Tablets, targeting children with low-grade glioma in China. This development highlights the company’s ongoing commitment to advancing innovative treatments and could potentially strengthen its position in the pharmaceutical market, offering new hope for pediatric patients with this condition.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on developing innovative drugs, with a market emphasis on treatments for various diseases, including cancer and neurological disorders.
Average Trading Volume: 6,887,271
Technical Sentiment Signal: Buy
Current Market Cap: HK$67.49B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.